Compounded Tirzepatide
a dual-incretin once-weekly injection
2.5 MG → 15 MG · 4-week vial supply
$193 for the first month, then $214 each month until canceled. Cancel anytime by emailing support@healthrx.com. Separate 12-month prepaid plans start at $179/mo equivalent. Medication, clinician review and shipping included.
We email you before any change to your renewal price or billing period. Subscription cancellation and refund terms.
- Free overnight shipping · all 50 states
- No insurance required
- MD-reviewed intake · US-licensed pharmacy
- If a licensed provider decides the treatment is not right for you, you are not charged for the medication.
Compare monthly GLP-1 plans
Compare the first payment and ongoing monthly price. These are monthly Subscribe & Save plans; prepaid plans have different payment schedules.
Medication, clinician review and shipping are included. Questions about moving your care? Contact our team before choosing a plan.
Tirzepatide acts on both GIP and GLP-1 receptors involved in glucose regulation and appetite. A clinician reviews your health history, medications, and treatment goals before deciding whether this compounded preparation is appropriate.
How it works in the body
Tirzepatide is a synthetic peptide that simultaneously activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). The combined agonism slows gastric emptying, suppresses appetite via central pathways in the hypothalamus, improves insulin sensitivity, and reduces food noise. A receptor mechanism alone does not predict an individual result or establish equivalence between different preparations.
The dose ladder.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 2.5 mg / week | Initiation. Most people feel nothing or mild nausea. |
| Weeks 05–08 | 5.0 mg / week | Appetite suppression becomes noticeable. |
| Weeks 09–12 | 7.5 mg / week | First provider check-in. Re-evaluate fit. |
| Weeks 13–16 | 10.0 mg / week | Most patients hold here as the working dose. |
| Weeks 17+ | 12.5–15 mg / week | Therapeutic maximum, only if tolerated and clinically appropriate. |
Questions for your care plan.
Side effects, honestly.
Common
- · Nausea (most common during titration)
- · Constipation
- · Diarrhea
- · Decreased appetite (the therapeutic effect)
- · Fatigue, mild headache
Serious
- · Pancreatitis (rare)
- · Gallbladder disease
- · Hypoglycemia (especially with other diabetes medications)
- · Possible thyroid C-cell tumors (animal studies in rats; relevance to humans unknown)
Who it's for. Who it isn't.
Suitable for
- · Adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related condition
- · Patients who have not responded to lifestyle changes alone
- · Patients whose clinician determines that the proposed preparation is appropriate
Not suitable for
- · Personal or family history of medullary thyroid carcinoma
- · Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- · History of severe pancreatitis
- · Pregnant or breastfeeding
- · Severe gastrointestinal disease
Questions, answered.
How much does compounded tirzepatide cost at HealthRX.com?
The monthly Subscribe & Save plan is $193 for the first month, then $214 per month. The price you see at checkout is the price billed. No insurance required.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active molecule in branded Mounjaro and Zepbound. The HealthRX.com preparation is compounded by a licensed 503A pharmacy on a valid, patient-specific prescription. It is not the branded product.
How much weight can I expect to lose on tirzepatide?
The SURMOUNT-1 trial studied a specific once-weekly injectable tirzepatide product, not the compounded preparation offered here. Its average results cannot predict your response. Your clinician sets treatment goals and reviews progress and tolerability with you.
What is the difference between tirzepatide and semaglutide?
Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors. The exact product, route, indication, clinical evidence, and your medical history matter when comparing treatment options.
Who should not take tirzepatide?
Tirzepatide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of severe pancreatitis, or during pregnancy or breastfeeding. A licensed clinician reviews your history before prescribing.
The published evidence.
- 01Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022.
- 02Garvey et al. Tirzepatide once weekly for chronic weight management (SURMOUNT-2). Lancet 2023.
- 03Wadden et al. SURMOUNT-3: tirzepatide after intensive lifestyle intervention. Nature Medicine 2023.
- 04FDA Prescribing Information: Mounjaro and Zepbound (tirzepatide).
CERT 50087439 · 503A PHARMACY
LICENSED CLINICIAN REVIEW
Researching your options? Explore the full GLP-1 medicine library or compare compounded semaglutide and compounded tirzepatide.